2017 American Transplant Congress
Pharmakokinetics of Daclatasvir, Sofosbuvir and GS-331007 in a Prospective Cohort of HCV Positive Kidney Transplant Recipients.
BackgroundLimited data exist on the pharmacokinetic (PK) profile of novel direct acting antivirals in kidney transplant recipients (KTR). Here we report the PK of combinated…2017 American Transplant Congress
A Phase Ib, Open Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End-Stage Renal Disease.
1U.Cincinnati, OH; 2Prolong Pharmaceuticals, NJ
Purpose:The endeavor and resources spent to study desensitization haven't been matched by an effort to investigate strategies to prevent sensitization.The purpose of this study was…2017 American Transplant Congress
Renal Secretion of Organic Anionic Drugs Is Compromised in Renal Transplant Patients.
Renal transplantation(Tx) is the treatment of choice for patients with ESRD. Transplanted kidneys undergo numerous insults including cold ischemia & warm reperfusion injury and are…2017 American Transplant Congress
The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model.
Purpose: Ischemia-reperfusion injury (IRI) is the strongest non-HLA factor that augments allogenicity of transplanted organs. Damage subsequent to IRI is critically linked to an abundance…2017 American Transplant Congress
Personalized Tacrolimus (TAC) Dosing Using Genetic Variants in Caucasian Kidney Transplant (Tx) Recipients.
TAC is an immune suppressant with a narrow therapeutic index and high pharmacokinetic (PK) variability leading to uncertainty in blood concentrations. We previously developed an…2017 American Transplant Congress
Benefits of Mycophenolate Sodium Over Mycophenolate Mofetil in Renal Transplant Patients Carrying UGT1A9 Polymorphism.
Nephrologist, Hospital Clínico San Carlos, Madrid, Spain
Aims: To analyze the differences in mycophenolic acid (MPA) pharmacokinetics and digestive side effects in renal transplant recipients on treatment with Mycophenolate mofetil (MMF) and…2017 American Transplant Congress
An Analysis of Tacrolimus XL Dosing in Obese Kidney Transplant Recipients.
Background:Tacrolimus extended-release (XL) is utilized in many immunosuppressive regimens post-kidney transplantation. Current dosing recommendation for the XL formulation in renal transplant (txp) is 0.15 mg/kg/day…2017 American Transplant Congress
Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem.
Background: Over the past 6 years we have prospectively used pharmacokinetic (PK) profiling of Tacrolimus (TAC) in “stable” RTR's to individualise future dosing. This study…2017 American Transplant Congress
One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has now been widely accepted in kidney transplant field. However, the optimal dosage for TACER is still not known.Patients…2017 American Transplant Congress
Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability, and Coefficient Variation.
Background: Tacrolimus, which plays a backbone in immunosuppressive therapy, has a different effect in absorption according to intraindividual and interindividual variability, and it is a…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »